Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 26, 2013

Primary Completion Date

June 2, 2017

Study Completion Date

June 2, 2017

Conditions
Coronary Artery Disease Progression
Interventions
DRUG

EPA and high dose rosuvastatin

After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.

DRUG

Standard dose rosuvastatin

After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.

All Listed Sponsors
lead

Kobe University

INDUSTRY

NCT03192579 - Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial | Biotech Hunter | Biotech Hunter